Explanipedia

Supplementary Table 5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open

Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu, Jun Li, Xiaogang Wu , et al. · 2025

RNASeq data for the MDA cohort (n=61) with associated clinical info.

Supplementary Figure S4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open

Ashley V. Menk, Dayana B. Rivadeneira, Mingchu Xu, Jun Li, Xiaogang Wu , et al. · 2025

Immune cell analysis by BMI. A. Immunohistochemistry (IHC) analysis for CD8-, CD45RO-, FOXP3-, CD68-, GZMB-, PD-1-, LAG-3-, and CD3-positive cells in overweight/obese (OW/OB) verse normal (NL) tumors as defined by body mass index from the …

Supplementary Figure S6 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open

Andrew W. Hahn, Ashley V. Menk, Ryan C. Augustin, Jun Li, Aditya K. Mishra , et al. · 2025

Direct metabolite measurements from a subset of The Cancer Genome Atlas (TCGA) cohort. Comparison of additional tricarboxylic acid cycle metabolites measured by liquid chromatography/mass spectrometry between metastatic melanoma tumors fro…

Supplementary Figure S8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open

Ashley V. Menk, Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu, Aditya K. Mishra , et al. · 2025

Inverse Simpson alpha diversity scores of the fecal microbiome by BMI in patients with metastatic melanoma stratified by sex. Box plot represents the median bar with the box bounding the IQR and whiskers the most extreme points within 1.5 …

Supplementary Table 2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open

Dayana B. Rivadeneira, Jun Li, Tuba N. Gide, Camelia Quek, Yan Zang , et al. · 2025

Differential gene expression analysis for covariates controlled.

Supplementary Figure S5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open

Ryan C. Augustin, Mingchu Xu, Jun Li, Xiaogang Wu, Aditya K. Mishra , et al. · 2025

Immune cell analysis by BMI and sex. A. Immunohistochemistry (IHC) analysis of the MDA cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor. B. IHC analysis of the Gide cohort…

Supplementary Figure S2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open

Ashley V. Menk, Jun Li, Xiaogang Wu, Aditya K. Mishra, Camelia Quek , et al. · 2025

Reverse phase protein array of the PI3K pathway expression by BMI. Box plot represents the median bar with the box bounding IQR and whiskers the minimum and maximum values.

Supplementary Figure S1 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open

Andrew W. Hahn, Ashley V. Menk, Ryan C. Augustin, Mingchu Xu, Jun Li , et al. · 2025

Integrated gene set enrichment analysis by body mass index (BMI) with correction for S phase. This figure presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients. Red indicates upregulation …

Supplementary Table 4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open

Andrew W. Hahn, Ashley V. Menk, Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu , et al. · 2025

Body mass index values by patient ID for all RNASeq cohorts.

Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma Open

Merve Hasanov, Simin Kiany, Marie‐Andrée Forget, Roland L. Bassett, Michael A. Davies , et al. · 2025

This study evaluated the efficacy and safety of unengineered tumor-infiltrating lymphocytes (TILs) combined with pembrolizumab and either high (HD, Arm-1) or low (LD, Arm-2) doses of IL-2 in patients with metastatic melanoma (MM). Patients…

Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Open

Elizabeth M. Burton, Denái R. Milton, Michael T. Tetzlaff, Khalida Wani, Merrick I. Ross , et al. · 2025

Immune checkpoint blockade (ICB) has revolutionized outcomes for patients with melanoma across multiple disease settings. In patients with advanced, unresectable disease, the ICB combination of nivolumab (anti-PD1) and relatlimab (anti–LAG…

Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis Open

Swaminathan Kumar, Meredith S. Pelster, Merve Hasanov, Renato Guerrieri, Courtney W. Hudgens , et al. · 2025

Melanoma brain metastases (MBMs) are diagnosed in up to 60% of metastatic melanoma patients. Previous studies have identified clinical factors that correlate with overall survival (OS) after MBM diagnosis. However, molecular and immune fea…

Meeting HighlightsThe 4th Marie Skłodowska-Curie Symposium on cancer research and care: Mechanisms of support for regional & international collaborations Open

Paweł Kaliński, Kathleen M. Kokolus, Indu B. Ahluwalia, Mihaela Balu, Łukasz Balwicki , et al. · 2025

The Marie Skłodowska-Curie Symposia on Cancer Research and Care (MSCS-CRC) promote collaborations between cancer researchers and care providers in the United States, Canada and Central and Eastern European Countries (CEEC) to accelerate th…

Expanded accrual and analysis of neoadjuvant plus adjuvant (neo+adj) dabrafenib (D) + trametinib (T) in patients (pts) with resectable stage (stg) III/IV melanoma Open

Elizabeth M. Burton, Ashley M. Holder, Michael W. Ross, Carlos A. Torres‐Cabala, M.T. Tetzlaff , et al. · 2025

Bills to Restrict Access to and Harm From Indoor Tanning Facilities in US State Legislatures, 1992‒2023 Open

David B. Buller, Julia Berteletti, Carolyn J. Heckman, Kevin R. J. Schroth, Alan C. Geller , et al. · 2024

Objectives. To describe progression, content, and stringency of state legislation regulating indoor tanning and association with state government political party leadership. Methods. Trained research assistants used legal mapping methods t…

The landscape of gain and loss of function mutations in melanoma Open

Noam Auslander, Konstantinos Tsingas, Monzy Thomas, Bryant Duong, Min Xiao , et al. · 2024

Melanoma is a common and aggressive cancer, with a rising incidence in most developed countries. Major discoveries in melanoma biology have been rapidly translated, allowing cures for some late-stage patients. Despite these advances, incom…

Health Economic Consequences Associated With COVID-19–Related Delay in Melanoma Diagnosis in Europe Open

Lara Valeska Maul, Dagmar Jamiolkowski, Rebecca A. Lapides, Alina Miriam Mueller, Axel Hauschild , et al. · 2024

Importance The COVID-19 pandemic resulted in delayed access to medical care. Restrictions to health care specialists, staff shortages, and fear of SARS-CoV-2 infection led to interruptions in routine care, such as early melanoma detection;…

Predicting sentinel node positivity in patients with primary cutaneous melanoma: an international multicentre study validating and refining the MIA risk calculator Open

Alexander H. R. Varey, Caroline A. Gjorup, Annette H. Chakera, L. Rosenkrantz Hölmich, Marc Moncrieff , et al. · 2024

Background: The Melanoma Institute Australia (MIA) sentinel node (SN) metastasis risk-prediction online calculator[Lo2020] is now widely used around the world. The tool comprises eight models that variously use between three and six input …

199 Quantitative and spatial characteristics of TIL in inflammatory neighborhoods of advanced melanoma tumors Open

Sühendan Ekmekçioglu, Sung-Nam Cho, Javier A. Gomez, Reham Abdel‐Wahab, Salah-Eddine Bentebibel , et al. · 2023

Background Immune checkpoint inhibitors (ICI) provide significant clinical benefits for advanced melanoma patients. However, most patients do not respond or develop resistance after initial tumor regression. In this ongoing study, we explo…

Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA) Open

Alexander Z. Wei, Lanyi Nora Chen, Marlana Orloff, Charlotte E. Ariyan, Maryam M. Asgari , et al. · 2023

Mucosal melanoma remains a rare cancer with high mortality and a paucity of therapeutic options. This is due in significant part to its low incidence leading to limited patient access to expert care and downstream clinical/basic science da…

1094P Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma Open

Elizabeth M. Burton, Denái R. Milton, L. Simpson, Michael T. Tetzlaff, Isabella C. Glitza , et al. · 2023

Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes Open

Samuel Cass, Brandon Cope, Andrew J. Bishop, Yi‐Ju Chiang, B. Ashleigh Guadagnolo , et al. · 2023

Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma Open

Russell G. Witt, Samuel Cass, Tiffaney Tran, Ashish Damania, Emelie E Nelson , et al. · 2023

Importance The gut microbiome modulates the immune system and responses to immunotherapy in patients with late-stage melanoma. It is unknown whether fecal microbiota profiles differ between healthy individuals and patients with melanoma or…

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy) Open

Paolo A. Ascierto, Sanjiv S. Agarwala, Allison Betof Warner, Marc S. Ernstoff, Bernard A. Fox , et al. · 2023

Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma Open

Anthony Lucci, Sridevi Addanki, Yi‐Ju Chiang, Salyna Meas, Vanessa N. Sarli , et al. · 2023

Stage III melanoma includes nodal metastasis or in-transit disease. Five-year survival rates vary between 32% and 93%. The identification of high-risk patients is important for clinical decision making. We demonstrated previously that ≥1 c…

Mitotic rate in primary cutaneous melanoma: Cell division matters Open

Jeffrey E. Gershenwald · 2023

The prognostic significance of primary cutaneous melanoma tumor mitotic rate (TMR) has been of worldwide clinical interest for decades. Is there a path forward to build on the contributions from the report by Patuzzo et al. and other studi…

Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma Open

John F. Thompson, John Hyngstrom, Corrado Caracò, Jonathan S. Zager, Tiina Jahkola , et al. · 2023

The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022 Open

Paolo A. Ascierto, Christian U. Blank, Alexander M.M. Eggermont, Claus Garbe, Jeffrey E. Gershenwald , et al. · 2023

Data from Mutational and Functional Analysis Reveals <i>ADAMTS18</i> Metalloproteinase as a Novel Driver in Melanoma Open

Xiaomu Wei, Todd D. Prickett, Cristina G. Viloria, Alfredo Molinolo, Jimmy Lin , et al. · 2023

The disintegrin-metalloproteinases with thrombospondin domains (ADAMTS) genes have been suggested to function as tumor suppressors as several have been found to be epigenetically silenced in various cancers. We performed a mutational analy…

Table S3 from Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases Open

Grant M. Fischer, Ali Jalali, David A. Kircher, Won‐Chul Lee, Jennifer L. McQuade , et al. · 2023

Table S3: Pathway Analysis of Intracranial and Subcutaneous Melanoma Xenografts. Results of EGSEA analyses of ICr (n=3) vs. SQ (n=3) tumors of 4 melanoma cell lines implanted into CD-1 nude mice. RNA-seq data were processed via Xenome to f…

Jeffrey E. Gershenwald YOU? Author Swipe